^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CLM-101
i
Other names: CLM-101, YYB101, NOV1105
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CellabMed, National OncoVenture
Drug class:
Hepatocyte growth factor inhibitor
Related drugs:
over1year
A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201) (ESMO 2023)
Conclusions The YYB101 and irinotecan combination showed modest efficacy and tolerable adverse events in refractory metastatic/recurrent CRC. Ongoing biomarker analyses aim to identify genomic and transcriptomic variables associated with long-term disease control.
Clinical • P1/2 data • PK/PD data • Combination therapy • Metastases
|
HGF (Hepatocyte growth factor)
|
irinotecan • CLM-101
over4years
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. (PubMed, Ther Adv Med Oncol)
Based on this phase I trial, a phase II study on the YYB101 + irinotecan combination in refractory metastatic colorectal cancer patients is planned. ClinicalTrials.gov Identifier: NCT02499224.
Clinical • P1 data • Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • HGF (Hepatocyte growth factor) • MAPK1 (Mitogen-activated protein kinase 1)
|
PD-L1 expression
|
irinotecan • CLM-101
Share via
